{"slug":"eortc","tag":"eortc","variants":["eortc"],"description":"No description yet","count":3,"kinds":{"person":3},"related":[{"slug":"chemotherapy","tag":"chemotherapy","shared":2},{"slug":"aya","tag":"aya","shared":1},{"slug":"glioma","tag":"glioma","shared":1},{"slug":"head-and-neck","tag":"head-and-neck","shared":1},{"slug":"sarcoma","tag":"sarcoma","shared":1}],"records":[{"id":"martin-van-den-bent","kind":"person","name":"Martin J. van den Bent","route":"/people/martin-van-den-bent/","tldr":"Led the EORTC glioma trials that established chemotherapy for anaplastic gliomas and the value of 1p/19q and IDH status."},{"id":"jan-vermorken","kind":"person","name":"Jan B. Vermorken","route":"/people/jan-vermorken/","tldr":"Led EXTREME and TAX 323, which defined the chemotherapy standards for head and neck cancer for a decade."},{"id":"winette-van-der-graaf","kind":"person","name":"Winette T. A. van der Graaf","route":"/people/winette-van-der-graaf/","tldr":"Led PALETTE, the trial that made pazopanib the first targeted drug for soft-tissue sarcoma."}]}